Overview

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with fibrotic lung disease.
Phase:
Phase 3
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil